Leyden Labs
Healthcare & Life Sciences
Recent Finacing
Equity
Recent Raise
$70M
Leyden Labs develops non-vaccine intranasal antibody treatments to protect against respiratory viruses like influenza and coronaviruses.
Focus Areas
Mucosal Protection
Intranasal Antibody
Respiratory Viruses
Pandemic Preparedness
Nasal Spray Technology
Investors
